Nature Communications (Sep 2019)

CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors

  • Linchun Jin,
  • Haipeng Tao,
  • Aida Karachi,
  • Yu Long,
  • Alicia Y. Hou,
  • Meng Na,
  • Kyle A. Dyson,
  • Adam J. Grippin,
  • Loic P. Deleyrolle,
  • Wang Zhang,
  • Didier A. Rajon,
  • Qiong J. Wang,
  • James C. Yang,
  • Jesse L. Kresak,
  • Elias J. Sayour,
  • Maryam Rahman,
  • Frank J. Bova,
  • Zhiguo Lin,
  • Duane A. Mitchell,
  • Jianping Huang

DOI
https://doi.org/10.1038/s41467-019-11869-4
Journal volume & issue
Vol. 10, no. 1
pp. 1 – 13

Abstract

Read online

CAR T-cell therapy efficacy in solid tumors is limited by inadequate T-cell migration and/or persistence in tumour microenvironment. Here, the authors show that the activity of tumour-antigen specific CAR T cells, in multiple preclinical mouse models, can be enhanced by co-expression of two IL-8 receptors that mediate their migration into the tumor microenvironment when IL-8 production in tumor is naturally expressed or enhanced by radiation.